Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
Resistance to ALK inhibitors such as lorlatinib often arise due to on-target mutations. Here, the authors show the multi-kinase inhibitor gilteritinib is effective against different mutations that arise during lorlatinib in ALK fusion positive lung cancer to cause resistance.
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/57a69b4d14e444839652b6a01ced7b32 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|